Ingenol disoxate - LEO Pharma

Drug Profile

Ingenol disoxate - LEO Pharma

Alternative Names: LEO-43204

Latest Information Update: 29 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma
  • Class Antiacnes; Antineoplastics; Carboxylic acids; Cyclopropanes; Esters; Isoxazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis; Squamous cell cancer
  • Phase II Acne vulgaris

Most Recent Events

  • 15 Jun 2018 LEO Pharma terminates a phase III trial in Squamous cell carcinoma (Prevention, Second-line therapy or greater, In adolescents, In adults, In children, In the elderly) in USA, Canada, France, Germany, Spain and United Kingdom (NCT03115476)
  • 01 Nov 2017 LEO Pharma completes a phase III trial for Actinic keratosis in United Kingdom and USA (Topical) (EudraCT2015-002449-71) (NCT02547233)
  • 10 Aug 2017 LEO Pharma completes a phase III trial in Actinic keratosis in USA and Germany (NCT02549339)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top